Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Mayank Mamtani - Riley Securities Albert Lowe - Craig-Hallum Sean McCutcheon - Raymond James Operator Thank you for standing by. My name is Rochelle and I wi ...

Core Viewpoint - NKGen Biotech has initiated the administration of troculeucel, an autologous NK cell therapy, to a stroke patient under a compassionate use IND approved by the FDA, marking a significant step in exploring its therapeutic potential in post-stroke treatment [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous and allogeneic NK cell therapeutics, headquartered in Santa Ana, California [7]. Product Development - Troculeucel is a novel, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate, being developed for neurodegenerative disorders and various cancers. The WHO has assigned the International Nonproprietary Name (INN) "troculeucel" for SNK01, which is a significant milestone for the company [6]. Clinical Collaboration - NKGen is collaborating with Dr. Dimitri Sigounas and Dr. Amarendra K. Neppalli from George Washington University Medical Center to explore the potential of troculeucel in reducing chronic neuroinflammation and damage in stroke patients [3][5]. Clinical Assessment - The stroke patient receiving troculeucel will undergo regular independent assessments by Dr. Sigounas at GWU Medical Center to evaluate the treatment's effectiveness [4]. Research Insights - Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are identified as markers of brain injury, and previous trials have shown that troculeucel can cross the blood-brain barrier to reduce cerebrospinal fluid levels of these markers, indicating its potential to improve outcomes in stroke patients [5].

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Conference Call February 28, 2025 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners Ram Selvaraju - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Longeveron 2024 and Full Year Financial Results Conference Call. At this time all participants are in a listen-only mode. ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barclays Ben Burnett - Stifel Colleen Kusy - Baird Yanan Zhu - Wells Fargo Securities Asthika Goonewardene - Truist Reni ...

Core Viewpoint - Mustang Bio, Inc. has exited its lease for a manufacturing facility in Worcester, Massachusetts, and divested certain fixed assets to AbbVie for $1.0 million, while relocating its corporate headquarters to Waltham, Massachusetts [1][2]. Group 1: Financial Implications - The termination of the lease is expected to result in approximately $2.0 million in cash expense savings over the next 24 months [2]. - The divestment of fixed assets to AbbVie Bioresearch Center Inc. was completed for a total of $1.0 million [1]. Group 2: Strategic Focus - The company remains committed to advancing its existing portfolio and plans to initiate a novel clinical trial with MB-109, targeting recurrent glioblastoma and high-grade astrocytomas in the second half of 2025 [3]. - MB-109 is a combination therapy that includes MB-101 (IL13Rα2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), aimed at enhancing the efficacy of CAR-T cell therapy by modifying the tumor microenvironment [4]. Group 3: Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, partnering with leading medical institutions to advance CAR-T therapies [5].

Core Insights - FibroBiologics has completed its proprietary master cell bank for the CYWC628 drug product, which will support upcoming clinical trials for diabetic foot ulcers [1][3][4] - The master cell bank was manufactured in compliance with FDA Good Manufacturing Practices (cGMP) and has passed all required safety testing [1][3] - The CYWC628 therapy targets diabetic foot ulcers, a condition affecting millions globally, and aims to provide effective long-term treatment solutions [3][4] Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 160 patents [2][8] - The company is exploring treatments for various conditions, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, human longevity, and cancer [2][8] Collaboration and Manufacturing - Charles River Laboratories will manufacture the CYWC628 cell banks and drug product at its state-of-the-art cGMP facilities, facilitating the upcoming phase I/II clinical trial [3][4] - The partnership between FibroBiologics and Charles River aims to expedite the development of advanced therapies and ensure readiness for scaling the CYWC628 product [4]

Gilead Sciences (GILD) Conference February 14, 2023 11:20 AM ET Speaker0 Great. Good morning, everybody, and thank you for joining us for this next session with Gilead. On behalf of SVB Securities, I'm very pleased to host Murdad Parsi from the company to discuss the company's pipeline prospects. And so, Murdad, it would be great for you to maybe just comment at a, you know, very briefly at a high level about the position you see Gilead in today versus, you know, obviously where it was even just nine to twe ...